Amundsen Ellen J, Melsom Anne-Karine M, Eriksen Bjørn O, Løchen Maja-Lisa
Department of Alcohol, Tobacco and Drugs, Norwegian Institute of Public Health, Oslo, Norway.
Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Centre for Clinical Research and Education, University Hospital of North Norway, Tromsø, Norway.
Nordisk Alkohol Nark. 2024 Feb;41(1):111-130. doi: 10.1177/14550725231195413. Epub 2023 Sep 28.
This Norwegian case study examines groups at risk of drug overdose deaths, evidence-based harm reduction interventions, low-threshold services and treatment implemented, as well as trends in drug overdose deaths between 2010 and 2021. We aimed to explore the relevance of interventions for at-risk groups and discuss their potential impact on drug overdose trends. Using an ecological approach, we analysed the following: (1) groups identified through latent profile analysis (LPA) among a sample of 413 high-risk drug users collected in 2010-2012, supplemented with other relevant studies up to 2021; (2) published information on harm-reduction interventions, low-threshold services and treatment in Norway; and (3) nationwide drug overdose mortality figures supplemented with published articles on the topic. High-risk drug users in 2010-2012 commonly engaged in frequent illegal drug use, injecting and poly-drug use (including pharmaceutical opioids), which continued into following decade. The interventions implemented between 2010 and 2021 were relevant for at-risk groups identified in the surveys. However, there was no decrease in the trend of drug overdose deaths up to 2021. While relevant interventions may have mitigated a theoretical increase in mortality, new at-risk groups may have contributed to fatal outcomes associated with pharmaceutical opioids. The interventions were relevant to the risk groups identified among high-risk drug users and potentially effective in preventing an increase in drug overdose trends. However, tailored interventions are needed for individuals at risk of death from prescribed opioids. Comprehensive studies encompassing all at-risk populations, including both legal and non-medical users of prescription opioids, are needed.
这项挪威案例研究考察了药物过量致死风险群体、基于证据的减少伤害干预措施、实施的低门槛服务和治疗,以及2010年至2021年期间药物过量致死的趋势。我们旨在探讨干预措施对风险群体的相关性,并讨论其对药物过量趋势的潜在影响。采用生态方法,我们分析了以下内容:(1)通过潜在类别分析(LPA)在2010 - 2012年收集的413名高风险吸毒者样本中确定的群体,并补充了截至2021年的其他相关研究;(2)挪威关于减少伤害干预措施、低门槛服务和治疗的已发表信息;(3)全国范围内的药物过量死亡率数据,并补充了关于该主题的已发表文章。2010 - 2012年的高风险吸毒者通常频繁使用非法药物、注射和使用多种药物(包括药用阿片类药物),这种情况持续到了接下来的十年。2010年至2021年实施的干预措施与调查中确定的风险群体相关。然而,截至2021年,药物过量致死的趋势并未下降。虽然相关干预措施可能减轻了理论上的死亡率上升,但新的风险群体可能导致了与药用阿片类药物相关的致命后果。这些干预措施与在高风险吸毒者中确定的风险群体相关,并且可能有效地防止药物过量趋势的增加。然而,对于有因处方阿片类药物死亡风险的个体,需要量身定制的干预措施。需要进行涵盖所有风险人群的综合研究,包括处方阿片类药物的合法和非医疗使用者。